# Chuan‐Ming Hao

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/chuan-ming-hao/

## Facts

| Field | Value |
| --- | --- |
| Citations | 13,194 |
| Field | Dialysis and Renal Disease Management |
| h-index | 58 |
| i10-index | 147 |
| Last Known Institution | Fudan University |
| OpenAlex ID | https://openalex.org/A5048018294 |
| ORCID iD | 0000-0002-4307-0987 |
| Works | 284 |

## Researcher papers

- [Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial](https://scholariq.org/papers/abbreviated-course-of-radiation-therapy-in-older-patients-with-glioblastoma/)
- [Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis](https://scholariq.org/papers/roxadustat-treatment-for-anemia-in-patients-undergoing-long-term-dialysis/)
- [Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial](https://scholariq.org/papers/atrasentan-and-renal-events-in-patients-with-type-2-diabetes-and-chronic-kidney/)
- [Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption](https://scholariq.org/papers/thiazolidinediones-expand-body-fluid-volume-through-ppar-stimulation-of-enac/)
- [Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis](https://scholariq.org/papers/roxadustat-for-anemia-in-patients-with-kidney-disease-not-receiving-dialysis/)
- [Sirt1 activation protects the mouse renal medulla from oxidative injury](https://scholariq.org/papers/sirt1-activation-protects-the-mouse-renal-medulla-from-oxidative-injury/)
- [Primacy of the 3B Approach to Control Risk Factors for Cardiovascular Disease in Type 2 Diabetes Patients](https://scholariq.org/papers/primacy-of-the-3b-approach-to-control-risk-factors-for-cardiovascular-disease-in/)
- [Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II](https://scholariq.org/papers/opposite-effects-of-cyclooxygenase-1-and-2-activity-on-the-pressor-response-to/)
- [Physiological Regulation of Prostaglandins in the Kidney](https://scholariq.org/papers/physiological-regulation-of-prostaglandins-in-the-kidney/)
- [Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study](https://scholariq.org/papers/risk-of-non-fatal-cardiovascular-diseases-in-early-onset-versus-late-onset-type/)
- [Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy](https://scholariq.org/papers/obinutuzumab-versus-rituximab-for-the-treatment-of-refractory-primary-membranous/)

## Researcher topics

- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Acute Kidney Injury Research](https://scholariq.org/topics/acute-kidney-injury-research/)
- [Parathyroid Disorders and Treatments](https://scholariq.org/topics/parathyroid-disorders-and-treatments/)

## Researcher university

- [Fudan University](https://scholariq.org/institutions/fudan-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.